Tibsovo (ivosidenib)

News alerts, weekly reports and conference planners

Company:

CStone Pharma, Sagard Healthcare, Schrodinger, Servier

Drug class:

IDH1 inhibitor

Related drugs:

IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 R132	Acute Myelogenous Leukemia	IDH1 R132	Acute Myelogenous Leukemia	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 mutation	Myelodysplastic Syndrome	IDH1 mutation	Myelodysplastic Syndrome	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 R132	Cholangiocarcinoma	IDH1 R132	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 mutation	Sarcoma	IDH1 mutation	Sarcoma	ivosidenib Sensitive: A2 - Guideline ivosidenib Sensitive : A2	ivosidenib Sensitive: A2 - Guideline ivosidenib Sensitive : A2
IDH1 mutation	Glioma	IDH1 mutation	Glioma	ivosidenib Sensitive: C1 - Off-label ivosidenib Sensitive : C1	ivosidenib Sensitive: C1 - Off-label ivosidenib Sensitive : C1
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C2 – Inclusion Criteria venetoclax + ivosidenib Sensitive : C2	venetoclax + ivosidenib Sensitive: C2 – Inclusion Criteria venetoclax + ivosidenib Sensitive : C2
IDH1 R132C	Cholangiocarcinoma	IDH1 R132C	Cholangiocarcinoma	ivosidenib Sensitive: C2 – Inclusion Criteria ivosidenib Sensitive : C2	ivosidenib Sensitive: C2 – Inclusion Criteria ivosidenib Sensitive : C2
NPM1 mutation + NRAS mutation	Acute Myelogenous Leukemia	NPM1 mutation + NRAS mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
KRAS mutation	Acute Myelogenous Leukemia	KRAS mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
KIT mutation	Acute Myelogenous Leukemia	KIT mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
TNFRSF10D expression	Acute Myelogenous Leukemia	TNFRSF10D expression	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
PTGS2 expression	Acute Myelogenous Leukemia	PTGS2 expression	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
RNF217-AS1 expression	Acute Myelogenous Leukemia	RNF217-AS1 expression	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
TFRC expression	Acute Myelogenous Leukemia	TFRC expression	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
GAS1 expression	Acute Myelogenous Leukemia	GAS1 expression	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
NAV3 expression	Acute Myelogenous Leukemia	NAV3 expression	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
RET expression	Acute Myelogenous Leukemia	RET expression	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
IDH1 mutation	Myelodysplastic Syndrome	IDH1 mutation	Myelodysplastic Syndrome	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
MYC overexpression + IDH2 mutation	Acute Myelogenous Leukemia	MYC overexpression + IDH2 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
MYC overexpression + IDH1 mutation	Acute Myelogenous Leukemia	MYC overexpression + IDH1 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
IDH2 mutation	Glioma	IDH2 mutation	Glioma	ivosidenib Sensitive: C3 – Early Trials ivosidenib Sensitive : C3	ivosidenib Sensitive: C3 – Early Trials ivosidenib Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
IDH1 mutation	Chronic Myeloid Leukemia	IDH1 mutation	Chronic Myeloid Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
IDH1 R132H + PTEN C78T	Acute Myelogenous Leukemia	IDH1 R132H + PTEN C78T	Acute Myelogenous Leukemia	ivosidenib Sensitive: C4 – Case Studies ivosidenib Sensitive : C4	ivosidenib Sensitive: C4 – Case Studies ivosidenib Sensitive : C4
IDH1 R132C + IDH1 S280F	Acute Myelogenous Leukemia	IDH1 R132C + IDH1 S280F	Acute Myelogenous Leukemia	ivosidenib Resistant: C4 – Case Studies ivosidenib Resistant : C4	ivosidenib Resistant: C4 – Case Studies ivosidenib Resistant : C4
IDH1 R132C + PIK3CA E545K + IDH2 R172K	Cholangiocarcinoma	IDH1 R132C + PIK3CA E545K + IDH2 R172K	Cholangiocarcinoma	ivosidenib Resistant: C4 – Case Studies ivosidenib Resistant : C4	ivosidenib Resistant: C4 – Case Studies ivosidenib Resistant : C4

Tibsovo (ivosidenib)

Associations
(34)

Associations
(34)

Tibsovo (ivosidenib)

Associations(34)

Associations(34)

Associations
(34)

Associations
(34)